Kathrin Milbury1, Jing Li2, Shiao-Pei Weathers3, Smitha Mallaiah4, Terri Armstrong5, Yisheng Li6, Eduardo Bruera4, Lorenzo Cohen4. 1. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston. 3. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston. 4. Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston. 5. Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 6. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
Abstract
BACKGROUND: While the use of behavioral medicine in managing glioma patients' symptoms is not well studied, the high symptom burden in patients and their family caregivers is well established. We conducted a pilot randomized, controlled trial to examine the feasibility and preliminary efficacy of a dyadic yoga (DY) intervention as a supportive care strategy. METHODS: Glioma patients undergoing radiotherapy and their caregivers were randomized to a 12-session DY or waitlist control (WLC) group. Prior to radiotherapy and randomization, both groups completed measures of cancer-related symptoms (MD Anderson Symptom Inventory-Brain Tumor module), depressive symptoms (Center for Epidemiological Studies-Depression measure), fatigue (Brief Fatigue Inventory), and overall quality of life (QOL; Medical Outcomes Study 36-item short-form survey). Dyads were reassessed at the last day of radiotherapy. RESULTS: Twenty patients (mean age: 46 years, 50% female, 80% WHO grade IV and caregivers (mean age: 50 years, 70% female, 50% spouses) participated in the trial. A priori feasibility criteria were met regarding consent (70%), adherence (88%), and retention (95%) rates. Controlling for relevant covariates, change score analyses revealed clinically significant improvements for patients in the DY compared with the WLC group for overall cancer symptom severity (d = 0.96) and symptom interference (d = 0.74), depressive symptoms (d = 0.71), and mental QOL (d = 0.69). Caregivers in the DY group reported clinically significant improvements in depressive symptoms (d = 1.12), fatigue (d = 0.89), and mental QOL (d = 0.49) relative to those in the WLC group. CONCLUSION: A DY intervention appears to be a feasible and beneficial symptom and QOL management strategy for glioma patients undergoing radiotherapy and their caregivers. An efficacy trial with a more stringent control group is warranted. CLINICAL TRIAL NUMBER: NCT02481349.
BACKGROUND: While the use of behavioral medicine in managing glioma patients' symptoms is not well studied, the high symptom burden in patients and their family caregivers is well established. We conducted a pilot randomized, controlled trial to examine the feasibility and preliminary efficacy of a dyadic yoga (DY) intervention as a supportive care strategy. METHODS: Glioma patients undergoing radiotherapy and their caregivers were randomized to a 12-session DY or waitlist control (WLC) group. Prior to radiotherapy and randomization, both groups completed measures of cancer-related symptoms (MD Anderson Symptom Inventory-Brain Tumor module), depressive symptoms (Center for Epidemiological Studies-Depression measure), fatigue (Brief Fatigue Inventory), and overall quality of life (QOL; Medical Outcomes Study 36-item short-form survey). Dyads were reassessed at the last day of radiotherapy. RESULTS: Twenty patients (mean age: 46 years, 50% female, 80% WHO grade IV and caregivers (mean age: 50 years, 70% female, 50% spouses) participated in the trial. A priori feasibility criteria were met regarding consent (70%), adherence (88%), and retention (95%) rates. Controlling for relevant covariates, change score analyses revealed clinically significant improvements for patients in the DY compared with the WLC group for overall cancer symptom severity (d = 0.96) and symptom interference (d = 0.74), depressive symptoms (d = 0.71), and mental QOL (d = 0.69). Caregivers in the DY group reported clinically significant improvements in depressive symptoms (d = 1.12), fatigue (d = 0.89), and mental QOL (d = 0.49) relative to those in the WLC group. CONCLUSION: A DY intervention appears to be a feasible and beneficial symptom and QOL management strategy for glioma patients undergoing radiotherapy and their caregivers. An efficacy trial with a more stringent control group is warranted. CLINICAL TRIAL NUMBER: NCT02481349.
Entities:
Keywords:
controlled trial; glioma; patient-caregiver dyads; pilot randomized; quality of life; yoga
Authors: Terri Armstrong; Marlene Z Cohen; Kenneth R Hess; Rochelle Manning; Eva Lu T Lee; Geline Tamayo; Karen Baumgartner; Sur J Min; Alfred Yung; Mark Gilbert Journal: J Pain Symptom Manage Date: 2006-08 Impact factor: 3.612
Authors: T S Armstrong; T Mendoza; I Gning; I Gring; C Coco; M Z Cohen; L Eriksen; Ming-Ann Hsu; M R Gilbert; C Cleeland Journal: J Neurooncol Date: 2006-04-06 Impact factor: 4.130
Authors: M Klein; M J Taphoorn; J J Heimans; H M van der Ploeg; W P Vandertop; E F Smit; S Leenstra; C A Tulleken; W Boogerd; J S Belderbos; W Cleijne; N K Aaronson Journal: J Clin Oncol Date: 2001-10-15 Impact factor: 44.544
Authors: N Scott Litofsky; Elana Farace; Frederick Anderson; Christina A Meyers; Wei Huang; Edward R Laws Journal: Neurosurgery Date: 2004-02 Impact factor: 4.654
Authors: Kavelin Rumalla; Michelle Lin; Elliot Orloff; Li Ding; Gabriel Zada; William Mack; Frank Attenello Journal: World Neurosurg Date: 2020-07-16 Impact factor: 2.104
Authors: Carolina X Sandler; Misa Matsuyama; Tamara L Jones; John Bashford; Danette Langbecker; Sandra C Hayes Journal: J Neurooncol Date: 2021-04-28 Impact factor: 4.130